Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolin Therapeutics has obtained an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment.
Subscribe to our email newsletter
The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents.
Donald Picker, president and COO of Oncolin, said: “We will work closely with both the Pharmaceutical Research Institute of Warsaw Poland and the University of Texas MD Anderson Cancer Center to further evaluate the compounds’s anticancer activity in order to advance a lead compound into clinical development.”